Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

Paul E. Dato, MD, discusses how a 69-year-old Black man presented with metastatic hormone-sensitive prostate cancer, showing symptoms of fatigue, nocturia, back pain, and weight loss, with initial ...

Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...

Paul E. Dato, MD, discusses how when selecting abiraterone for metastatic hormone-sensitive prostate cancer patients, there are 3 formulations to consider: standard, generic, and micronized versions, ...

The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant radiographic ...